![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 4
2018
Marshall, Alison D.; Cunningham, Evan B.; Nielsen, Stine; Aghemo, Alessio; Alho, Hannu; Backmund, Markus; Bruggmann, Philip; Dalgard, Olav; Seguin-Devaux, Carole; Flisiak, Robert; Foster, Graham R.; Gheorghe, Liana; Goldberg, David; Goulis, Ioannis; Hickman, Matthew; Hoffmann, Patrick; Jancoriene, Ligita; Jarcuska, Peter; Kaberg, Martin; Kostrikis, Leondios G.; Makara, Mihaly; Maimets, Matti; Marinho, Rui Tato; Maticic, Mojca; Norris, Suzanne; Olafsson, Sigurour; Ovrehus, Anne; Pawlotsky, Jean-Michel; Pocock, James; Robaeys, Geert; Roncero, Carlos; Simonova, Marieta; Sperl, Jan; Tait, Michele; Tolmane, Ieva; Tomaselli, Stefan; Valk, Marc van der; Vince, Adriana; Dore, Gregory J.; Lazarus, Jeffrey V. und Grebely, Jason
(2018):
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe.
In: Lancet Gastroenterology & Hepatology, Bd. 3, Nr. 2: S. 125-133
2017
Grebely, Jason; Dalgard, Olav; Cunningham, Evan B.; Hajarizadeh, Behzad; Foster, Graham R.; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Amin, Janaki; Marks, Philippa S.; Quiene, Sophie; Applegate, Tanya L.; Weltman, Martin; Shaw, David; Dunlop, Adrian; Hellard, Margaret; Bruneau, Julie; Midgard, Havard; Bourgeois, Stefan; Stähelin, Cornelia und Dore, Gregory J.
(2017):
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
In: International Journal of Drug Policy, Bd. 47: S. 177-186
Midgard, Havard; Hajarizadeh, Behzad; Cunningham, Evan B.; Conway, Brian; Backmund, Markus; Bruggmann, Philip; Bruneau, Julie; Bourgeois, Stefan; Dunlop, Adrian; Foster, Graham R.; Hellard, Margaret; Robaeys, Geert; Thurnheer, Maria C.; Weltman, Martin; Amin, Janaki; Marks, Philippa S.; Quiene, Sophie; Dore, Gregory J.; Dalgard, Olav und Grebely, Jason
(2017):
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
In: International Journal of Drug Policy, Bd. 47: S. 230-238
Cunningham, Evan B.; Hajarizadeh, Behzad; Dalgard, Olav; Amin, Janaki; Hellard, Margaret; Foster, Graham R.; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Marks, Philippa S.; Quiene, Sophie; Applegate, Tanya L.; Weltman, Martin; Shaw, David; Dunlop, Adrian; Bruneau, Julie; Midgard, Havard; Bourgeois, Stefan; Thurnheer, Maria Christine; Dore, Gregory J. und Grebely, Jason
(2017):
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
In: BMC infectious Diseases
17:420
[PDF, 646kB]